But what caught my eye and generated my pre-caffeine ire was in the opening sentence, terminology used in clinical pharmacology and therapeutics, words that I admit to have even uttered myself:
- WASHINGTON–The Food and Drug Administration Friday approved a new type of drug by Roche Holding AG’s Genentech unit to treat rheumatoid arthritis in patients who have failed other treatments. [emphasis mine]
I know that we use that phrase because it is seems less cumbersome than saying, “in patients whose disease has not responded to existing drugs.”
But saying that the patient failed the treatment makes it seems that the patient somehow bears responsibility for the lack of their disease to respond to the tools we currently have available. Yes, yes, I know – disease is essentially a patient’s own pathophysiology, where their own homeostatic mechanisms are awry or respond inappropriately to environmental changes or invading organisms.
But jeez, have you ever thought what it sounds like to a patient to hear that they failed the therapy? Could we possibly take any less responsibility for our failure to treat disease? Even if physicians want to use the word “fail” couldn’t they at least shift the blame to us basic scientists who’ve failed to come up with an alternative drug?
Read More: http://scienceblogs.com/terrasig/2010/01/did_the_patient_fail_the_treat.php (ScienceBlogs: Terra Sigillata)
U.S. approves Roche’s Actemra arthritis drug
WASHINGTON, Jan 08 (Reuters) – The U.S. Food and Drug Administration has approved Roche Holding AG’s (ROG.VX) Actemra to treat rheumatoid arthritis, the company said on Friday.
The drug, made by Roche’s Genentech unit, is already approved for use in Europe and Japan and is expected by the company to become a blockbuster product.
The FDA approved the drug for treatment of adults with moderate to severe rheumatoid arthritis who do not respond well enough to another class of biotech drugs designed to block an inflammatory protein called tumor necrosis factor (TNF).
Actemra is an anti-interleukin-6 receptor antibody and works differently from TNF blockers such as Humira, sold by Abbott Laboratories (ABT.N), and Remicade, sold by Johnson & Johnson (JNJ.N).
Is it wrinkled, gray, and crippled? Or – is it a child, a teenager, a ballet dancer, a professional athlete?
The truth is, it can be any of the above. Arthritis in its different forms can affect all ages and ethnicities.
I personally “don’t look sick” but at age 26 have multiple ongoing health problems, including Rheumatoid Arthritis that I’ve had since around the age of 10. Well-known NBA player Allan Iverson has recently been sidelined due to arthritis in his knee. We had an honoree for our Fall Walk, Deora, who was only 2 years old, and a Jingle Bell Run Honoree, Maddie, who was just 9 years of age. My grandmother has arthritis; but so does a friend of mine in her early 30’s. There is no set age when arthritis can strike, and the reality is, since there are so many different types, it can happen to just about anyone!
That being said, when it does happen to you — especially if you are a child or young adult — you may still feel like you ARE the only one. We’d like you to know that you are NOT alone!!
Read More: http://arthritisfoundationwpa.wordpress.com/2010/01/08/young-arthritis-resources-for-juvenile-arthritis-young-adults-living-with-arthritis-related-disease-ashley-boynes-community-development-director-wpa-chapter/
Rheum to Grow – A Facebook Page for Teens & Young Adults
I’m finding that there is very little information available about a combination of drugs I will be starting soon. I posted an entry on my blog about it but I’m having little to no luck. The combination I’m mostly concerned about is Rituxan and Humira. Supposedly its still a somewhat rare combo. Not to mention the methotrexate and Prednisone. I was hoping there was someone else who is on these that could give me some insight.
If you have already submitted information for a profile and it has not been published yet, please know that you have not been overlooked! The tremendous number of responses that I received, combined with the recent holidays, is causing me to publish them much later than I might have previously estimated. Thanks to everyone who has already submitted a profile – I continue to publish these profiles in the order in which they were received!
If you have not yet submitted a profile but would like to, please do let me know!